Hetlioz

Chemical Nametasimelteon
Dosage FormCapsule (oral; 20 mg); Suspension (oral; 4 mg/mL)
Drug ClassReceptor agonists
SystemEndocrine
CompanyVanda Pharmaceuticals
Approval Year2014

Indication

  • Capsules are indicated for the treatment of non-24-hour sleep-wake disorder (Non-24) in adults and nighttime sleep disturbances in Smith-Magenis syndrome (SMS) in patients 16 years of age and older.
  • Oral suspension is indicated for the treatment of nighttime sleep disturbances in SMS in pediatric patients 3 years to 15 years of age.
Last updated on 7/18/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Hetlioz (tasimelteon) Prescribing Information.2020Vanda Pharmaceuticals Inc., Washington, D.C.